Year: 2020

Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia

                                                                                                                                                            Rilzabrutinib granted FDA Fast Track Designation for treatment of immune thrombocytopenia Phase 3 trial initiated to evaluate rilzabrutinib, the...